Premium
Front Cover: Carborane‐Containing Matrix Metalloprotease (MMP) Ligands as Candidates for Boron Neutron‐Capture Therapy (BNCT) (ChemMedChem 20/2020)
Author(s) -
Lutz Marlon R.,
Flieger Sebastian,
Colorina Andre,
Wozny John,
Hosmane Narayan S.,
Becker Daniel P.
Publication year - 2020
Publication title -
chemmedchem
Language(s) - English
Resource type - Reports
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202000730
Subject(s) - matrix metalloproteinase , carborane , chemistry , metastability , ligand (biochemistry) , biophysics , front cover , cell , boron , matrix (chemical analysis) , cancer research , receptor , cover (algebra) , biochemistry , stereochemistry , medicine , biology , organic chemistry , mechanical engineering , chromatography , engineering
The Front Cover shows an idealized cell with a normal cell represented by the right half, with organelles and a variety of receptors on the surface, whereas a tumor cell is represented by the disordered left half of the cell. The carborane‐containing matrix metalloproteinase (MMP) inhibitor/ligand surrounds both healthy and tumor cells, but binds potently to the overexpressed gelatinase (MMP‐2 and MMP‐9) enzymes on the tumor surface. Incoming thermal neutrons from the left find the represented bullseye in the 10 B atoms in the carborane cluster leading to a metastable 11 B that undergoes fission releasing α and 7 Li particles that damage and ultimately destroy the tumor cell target. Cover design by Robert D. Becker. More information can be found in the Full Paper by Daniel P. Becker et al.